GLP-1S prices

FROM PEPTIDES CALCULATOR

About Semaglutide

Source profile reviewed 2026-10-01 · Imported 2026-10-22. Read the full compound profile

Semaglutide is a long-acting analog of the gut hormone glucagon-like peptide-1, developed by Novo Nordisk, in which an aminoisobutyric acid substitution blocks DPP-4 cleavage and a C18 fatty diacid side chain binds albumin to give a half-life of about a week. The FDA has approved it in four distinct products: Ozempic injection and Rybelsus tablets for type 2 diabetes, Wegovy injection for chronic weight management and cardiovascular risk reduction, and Wegovy tablets, approved in December 2025 as the first oral GLP-1 for obesity. Each product has its own escalation schedule and ceiling, from 2 mg weekly for Ozempic to 7.2 mg weekly for the high-dose Wegovy injection and 25 mg daily for Wegovy tablets. A large compounded and grey market also exists; the FDA declared the semaglutide injection shortage resolved in February 2025 and has since restricted the conditions under which pharmacies may compound copies.

Formula

C187 H291 N45 O59

Molar mass

4,114 g/mol

CAS number

910463-68-2

Amino acids

31

Research evidence described in the source

Limitations noted in the source

• Approved dosing depends on the exact product, indication, comorbidities, and prescribing information.
• Compounded or research-vial material is not interchangeable with an approved prefilled product.
• A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
• Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.

Background is reproduced from Peptides Calculator with attribution. The source describes compound-level research. It does not evaluate the identity, quality or suitability of a listed supplier’s product or batch.